预约演示
更新于：2025-09-05
Propafenone Hydrochloride
盐酸普罗帕酮
更新于：2025-09-05
概要
基本信息
药物类型 小分子化药 |
别名 1-(2-(2-hydroxy-3-(propylamino)propoxy)phenyl)-3-phenyl-1-propanone、2-(2'-hydroxy-3'-propylaminopropoxy)-ω-phenylpropiophenone、Propafenone + [16] |
作用方式 阻滞剂 |
作用机制 钠通道阻滞剂 |
治疗领域 |
非在研适应症 |
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 加拿大 (1988-01-01), |
最高研发阶段(中国)撤市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C21H28ClNO3 |
InChIKeyXWIHRGFIPXWGEF-UHFFFAOYSA-N |
CAS号34183-22-7 |
关联
30
项与 盐酸普罗帕酮 相关的临床试验ChiCTR2500098501
Study on the 90% effective dose of phosphoprofen combined with fentanyl in adult colonoscopy using the BCD-UDM sequential method
CTR20242812
盐酸普罗帕酮片人体生物等效性试验
NCT05939076
First-line Cryoablation for Early Treatment of Persistent Atrial Fibrillation - a Randomized Study Comparing Early Trigger Isolation Using the Cryoballoon Versus Antiarrhythmic Medication
100 项与 盐酸普罗帕酮 相关的临床结果
登录后查看更多信息
100 项与 盐酸普罗帕酮 相关的转化医学
登录后查看更多信息
100 项与 盐酸普罗帕酮 相关的专利（医药）
登录后查看更多信息
2,595
项与 盐酸普罗帕酮 相关的文献（医药）2025-11-01SEPARATION AND PURIFICATION TECHNOLOGY
Experimental characterization and QSAR modeling of maximum uptake and distribution factor for neutral and ionic micropollutants on granular activated carbon in artificial and real wastewaters
作者: Cho, Chul-Woong ; Park, Si-Hyeon ; Lee, Kwan-Yong ; Cho, Bo-Gyeon ; Jin, Se-Ra ; Cheon, Jeong-Min
Granular activated carbon (GAC)-based adsorption treatment for micropollutant removal is known to be cost-effective and environmentally sustainable.However, an efficient method is urgently needed to assess the applicability of GAC for a diverse range of micropollutants in various wastewater conditions.Therefore, we developed predictive models to determine the maximum uptake (qmax; calculated by the Langmuir model) and distribution factor (KF; calculated by the Freundlich model) of a range of micropollutants on GAC, which can help overcome exptl. limitations, save resources and time, and provide a deeper understanding of adsorption mechanisms.Exptl. isotherms for controlled conditions to obtain the qmax and KF were performed for both artificial and real wastewaters. qmax values of micropollutants were similar in both wastewaters, but KF values differed slightly.Exptl. obtained qmax and KF values were used in linear free energy relationship-based predictive modeling.The results showed reasonable predictive accuracy for qmax, with R2 values ranging from 0.844 to 0.875 and standard errors between 0.144 and 0.072 log units for both artificial and real wastewater conditions.For KF, the model showed R2 values between 0.803 and 0.762, with standard errors ranging from 0.189 to 0.163 log units.The two models showed high potential for use in GAC-based micropollutant removal.
2025-09-02INTERNATIONAL JOURNAL OF ENVIRONMENTAL ANALYTICAL CHEMISTRY
Development and application of a sustainable approach for the determination of 95 pharmaceutical substances and metabolites in urban wastewater by means of ultra-high-performance liquid-chromatography-tandem mass spectrometry
作者: Vincenti, Marco ; Gerace, Enrico ; Minella, Marco ; Privitera, Dana ; Salomone, Alberto ; Massano, Marta ; Alladio, Eugenio
In the last few years, the interest in pharmaceutical drugs and their metabolites as environmental pollutants is gaining growing importance.Regular monitoring and timely actions are decisive to implement appropriate water resource management strategies and to evaluate the efficiency of traditional or innovative wastewater treatment plants (WWTPs).This study describes the development and validation of an anal. procedure using 10 mL sample volume followed by direct-injection in ultra-high-performance liquid chromatog.-tandem mass spectrometry (UHPLC-MS/MS) for the simultaneous determination of 95 pharmaceutical drugs and 10 of their main metabolites in wastewater.Adequate sensitivity was recorded for all target analytes, with limits of detection below 5 ng/L for 60 out of 95 analytes and recoveries exceeding 80% for all the analytes under study.A total of 42 target analytes were detected in almost all sites, and limited differences were observed among several pharmaceutical drug arrays found at different sampling sites.In addition, an abatement yield higher than 50% was observed for only 12 of the 42 detected substances.The procedure, which combined direct injection and small sample volume collection, showed great potential and efficiency for the high-performance determination of pharmaceutical drugs in wastewater.
2025-09-01BIOCHIMIE
Repurposing of propafenone, an FDA approved anti-arrhythmic drug for antileishmanial therapy
Article
作者: Singh, Sushma ; Paul, Anindita ; Khan, Mohd Faiz ; Babu, Neerupudi Kishore ; Lalchhuanawmi, Sandra ; Roy, Pradyot Kumar
Elimination of the Neglected Tropical Disease Visceral Leishmaniasis (VL) is a Sustainable Development Goal. It is caused by Leishmania donovani. The therapeutic options for the treatment of VL are limited due to problems such as drug resistance and toxicities. Drug repurposing can be a promising alternative in this case. In this work, the antileishmanial potential of FDA approved anti-arrhythmic drug propafenone has been evaluated for repurposing. It reduced the viability of L. donovani promastigotes and intracellular amastigotes with an IC50 of 8.25 ± 2.48 μM and 11.19 ± 0.01 μM respectively. In the macrophages, the IC50 was 32 ± 7.07 μM. Propafenone treatment altered morphology of parasites and induced damage to the body and flagellum. The cell membrane became damaged and more permeable when the promastigotes were treated with this drug. However, no change in the cell membrane potential was detected. Treatment with propafenone was detrimental to mitochondrial health of L. donovani. It significantly depolarized the mitochondrial membrane and decreased the ATP levels in the promastigotes. Propafenone also induced oxidative stress in the parasites. Cell cycle arrest was detected at the G2/M stage. The data suggests that propafenone has antileishmanial potential and can be evaluated further in an experimental VL model.
58
项与 盐酸普罗帕酮 相关的新闻（医药）2025-09-01
2025-08-11
100 项与 盐酸普罗帕酮 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 室性心动过速 | 巴西 | 2015-09-14 | |
| 心房颤动 | 美国 | 1989-11-27 | |
| 心律失常 | 加拿大 | 1988-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 繭製繭淵觸襯蓋蓋淵繭(網遞廠廠鹽齋鹽網鏇窪) = 壓顧顧襯範繭壓壓壓廠 膚糧淵膚淵憲繭蓋壓膚 (鏇憲蓋構壓製膚觸選糧 ) 更多 | - | 2024-04-09 | |||
繭製繭淵觸襯蓋蓋淵繭(網遞廠廠鹽齋鹽網鏇窪) = 繭醖衊糧積獵壓鹹艱廠 膚糧淵膚淵憲繭蓋壓膚 (鏇憲蓋構壓製膚觸選糧 ) 更多 | |||||||
N/A | 505 | Antazoline mesylate | 顧蓋鹽糧窪壓齋窪簾壓(蓋蓋淵範簾醖願鹽選鏇) = 淵遞憲糧積獵鏇選鬱築 製製壓艱顧夢遞壓觸膚 (製淵壓膚廠醖選製遞膚 ) | 积极 | 2019-09-01 | ||
顧蓋鹽糧窪壓齋窪簾壓(蓋蓋淵範簾醖願鹽選鏇) = 壓鬱顧蓋製蓋蓋醖積鑰 製製壓艱顧夢遞壓觸膚 (製淵壓膚廠醖選製遞膚 ) | |||||||
N/A | 110 | Radiofrequency catheter ablation (AAD:NO) | 齋夢網願遞網範淵廠鑰 = 壓繭窪蓋鏇膚鏇壓獵顧 襯遞鹽選網襯顧鏇憲簾 (鏇鹽淵範構餘膚襯壓壓, 襯廠廠夢簾構夢壓糧齋 ~ 艱選淵艱鹽艱範鏇夢醖) 更多 | - | 2013-03-07 | ||
(AAD:YES) | 齋夢網願遞網範淵廠鑰 = 鏇衊遞膚膚鬱壓製繭窪 襯遞鹽選網襯顧鏇憲簾 (鏇鹽淵範構餘膚襯壓壓, 簾廠簾壓廠窪鹹構顧積 ~ 窪網築選衊膚衊憲齋夢) 更多 | ||||||
N/A | 60 | Ablation Therapy | 衊鏇窪鹹夢願觸衊廠蓋 = 構窪顧觸餘壓願襯鹽顧 壓壓齋範繭鏇憲觸膚衊 (壓壓鏇糧製壓繭鑰選網, 齋鑰遞構憲鬱廠獵構蓋 ~ 廠選衊艱獵壓鏇壓鬱餘) 更多 | - | 2013-01-04 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用